These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28512269)

  • 1. Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation.
    Templin J; Atanackovic D; Hasche D; Radhakrishnan SV; Luetkens T
    Oncotarget; 2017 Jul; 8(30):49253-49263. PubMed ID: 28512269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of interleukin 16 in multiple myeloma.
    Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
    J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR5 activation by flagellin induces doxorubicin resistance via interleukin-6 (IL-6) expression in two multiple myeloma cells.
    Cho HY; Lee SW
    Cell Immunol; 2014; 289(1-2):27-35. PubMed ID: 24709011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.
    Chen H; Li M; Campbell RA; Burkhardt K; Zhu D; Li SG; Lee HJ; Wang C; Zeng Z; Gordon MS; Bonavida B; Berenson JR
    Oncogene; 2006 Oct; 25(49):6520-7. PubMed ID: 16702955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
    Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
    J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for interleukin-6 and insulin-like growth factor-I via PI3-K/Akt pathway in the proliferation of CD56- and CD56+ multiple myeloma cells.
    Sahara N; Takeshita A; Ono T; Sugimoto Y; Kobayashi M; Shigeno K; Nakamura S; Shinjo K; Naito K; Shibata K; Otsuki T; Hayashi H; Ohnishi K
    Exp Hematol; 2006 Jun; 34(6):736-44. PubMed ID: 16728278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
    Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
    Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.
    Gocke CB; McMillan R; Wang Q; Begum A; Penchev VR; Ali SA; Borrello I; Huff CA; Matsui W
    Mol Cancer Ther; 2016 Nov; 15(11):2733-2739. PubMed ID: 27573425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells.
    Arendt BK; Velazquez-Dones A; Tschumper RC; Howell KG; Ansell SM; Witzig TE; Jelinek DF
    Leukemia; 2002 Oct; 16(10):2142-7. PubMed ID: 12357369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.
    Verdelli D; Nobili L; Todoerti K; Mosca L; Fabris S; D'Anca M; Pellegrino E; Piva R; Inghirami G; Capelli C; Introna M; Baldini L; Chiaramonte R; Lombardi L; Neri A
    Genes Chromosomes Cancer; 2014 Feb; 53(2):154-67. PubMed ID: 24327544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-IL-16 is associated with MHC class II-mediated negative regulation of mouse resting B cell activation through MAP kinases, NF-κB and Skp2-dependent p27kip regulation.
    Yang HY; Kim J; Kim SH; Choe CH; Jang YS
    Scand J Immunol; 2013 Mar; 77(3):177-86. PubMed ID: 23297678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
    Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson KC
    Oncogene; 2001 Jul; 20(33):4519-27. PubMed ID: 11494147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma.
    Kudo C; Yamakoshi H; Sato A; Ohori H; Ishioka C; Iwabuchi Y; Shibata H
    Anticancer Res; 2011 Nov; 31(11):3719-26. PubMed ID: 22110192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.
    Tu Y; Gardner A; Lichtenstein A
    Cancer Res; 2000 Dec; 60(23):6763-70. PubMed ID: 11118064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
    Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
    Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.
    Hideshima T; Nakamura N; Chauhan D; Anderson KC
    Oncogene; 2001 Sep; 20(42):5991-6000. PubMed ID: 11593406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB.
    Xu Y; Zhao Y; Huang H; Chen G; Wu X; Wang Y; Chang W; Zhu Z; Feng Y; Wu D
    Br J Haematol; 2010 Sep; 150(5):543-53. PubMed ID: 20629663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.